Thursday October 4, 2007 - Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness*... Immtech's Press Release [PDF]-
Friday, October 5, 2007
Immtech , Interim Analysis in Phase III African Sleeping Sickness Trial
Thursday October 4, 2007 - Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness*... Immtech's Press Release [PDF]-
